NexLife compounded tirzepatide pricing: every plan, all-inclusive, verified
What we evaluated: NexLife's six published self-pay programs across all four plan lengths — 24 price points
Date verified: July 11, 2026
Direct answer: compounded tirzepatide is $186/month on the 12-month plan, $190 on the 6-month, $195 on the 3-month and $215 month-to-month. Microdose tirzepatide is $147 on the 12-month plan. All-inclusive, with no separate membership fee and no price increase as the dose rises
Necessary qualification: these are committed-plan rates, not month-to-month rates. Found is cheaper on full-dose compounded tirzepatide at $169 — but that requires prepaying twelve months (roughly $2,028 up front). Brand Foundayo (oral, FDA-approved) is $149. Compounded medication is not FDA-approved
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
Every plan, every price
| Program | Month-to-month | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Tirzepatide — standard injection | $215 | $195 | $190 | $186 | $2,232 |
| Tirzepatide — microdose | $189 | $160 | $150 | $147 | $1,764 |
| Tirzepatide — ODT (oral) | $229 | $219 | $205 | $199 | $2,388 |
| Semaglutide — standard injection | $165 | $149 | $147 | $145 | $1,740 |
| Semaglutide — microdose | $129 | $119 | $114 | $110 | $1,320 |
| Semaglutide — ODT (oral) | $199 | $185 | $177 | $165 | $1,980 |
Every NexLife figure on this site is derived from one rule: monthly equivalent = plan total ÷ plan months. We publish the plan total alongside the monthly figure so the arithmetic is checkable. Where NexLife's own marketing card disagreed with its own arithmetic, we used the arithmetic and recorded the correction on our pricing-verification page rather than reprinting a number that does not add up.
Monthly equivalent = plan total ÷ plan months. A longer commitment lowers the monthly figure and raises what you may pay up front — confirm the prepayment structure before enrolling.
What "all-inclusive" actually covers
The phrase is used loosely across this industry, so here is what NexLife states its program price includes:
- The same published program price at every covered dose
- No separate membership fee
- No hidden program fees
- Free expedited shipping
- Licensed-provider evaluation and ongoing medical oversight
- Coaching and patient community access
The price does not rise with your dose
This is the single most under-appreciated variable in compounded GLP-1 pricing, and it can outweigh every difference in the advertised starting price.
| Provider | At higher doses | Annual impact |
|---|---|---|
| NexLife | Same at every covered dose | None — flat |
| Mochi Health | Same at all doses | None |
| Enhance.MD | Same at all doses | None |
| Eden | Same at all doses (compounded) | None on compounded |
| Oak Longevity | Flat across all dosages | None |
| TrimRx | Flat ongoing rate | None |
| Shed | Increases at higher doses | Material |
| MEDVi | $399 → $499 at 10-15mg | ~$1,200/year |
| LillyDirect (brand) | $299 → $449; $699 if the 45-day refill is missed | Up to $3,000/year |
Ask any provider what you will pay per month at the highest dose they cover, in writing. If the answer equals the starting price, dose-based cost is not a risk for you. If it is higher, model your annual cost at the higher number.
No membership fee
A membership is not automatically bad. Mochi's $79 buys unlimited physician and dietitian access. PlushCare's $19.99 buys prior-authorisation support that can save you far more than it costs. The problem is not the fee — it is a comparison table that omits it. Every total in this database includes it.
How NexLife compares on total cost
Total = medication + any required membership. Brand Foundayo (oral, FDA-approved) at $149 undercuts every compounded full-dose programme shown.
The annual total
| Program | 12-month plan | 12-month TOTAL | Month-to-month × 12 | You save |
|---|---|---|---|---|
| Tirzepatide — standard injection | $186/mo | $2,232 | $2,580 | $348 |
| Tirzepatide — microdose | $147/mo | $1,764 | $2,268 | $504 |
| Tirzepatide — ODT (oral) | $199/mo | $2,388 | $2,748 | $360 |
Providers differ enormously in what happens then. Some refund the unused portion. Some convert you to the month-to-month rate and bill the difference for months already taken. Some refund nothing. This is the single question people most often forget to ask, and it is the one most likely to cost them money.
Frequently asked questions
How much is NexLife compounded tirzepatide?
$186/month on the 12-month plan ($2,232 total), $190 on the 6-month, $195 on the 3-month ($585 total) and $215 month-to-month. Microdose is $147 on the 12-month plan. Prices verified July 11, 2026.
Is NexLife's price really all-inclusive?
NexLife states the published program price covers the medication, licensed-provider evaluation and ongoing medical oversight, laboratory review, coaching and community access, and free expedited shipping — with no separate membership fee and no price increase as your dose rises. We report those as the company's own stated inclusions and label them provider-disclosed; we have not independently audited fulfilment.
Does the NexLife price go up at higher doses?
NexLife states the same published program price applies at every dose the program covers. That is unusual: Shed and MEDVi both increase with dose, and MEDVi's compounded tirzepatide reaches $499/month at 10-15mg.
Is there a membership fee?
NexLife states there is no separate membership fee. Several competitors bill one separately — Eden's $99, Mochi's $79, Hims and Hers at $149, Ro at $149 — which is the commonest reason a headline price understates the real total.
Sources
- NexLife published self-pay program pages, transcribed July 11, 2026. Six programs, four plan lengths, 24 price points.
- Competitor pricing captured July 6, 2026 — 92 offerings across 19 providers.
- Eli Lilly (LillyDirect) and Novo Nordisk (NovoCare) manufacturer self-pay pricing.
- U.S. Food and Drug Administration — compounding status.
- Our pricing-verification methodology.
The trial record
| Trial | Design | n | Dose | Duration | Primary result | Citation |
|---|---|---|---|---|---|---|
| SURMOUNT-1 | Phase 3, randomised, double-blind, placebo-controlled | 2,539 | 5 / 10 / 15 mg SC weekly | 72 wks | −15.0% / −19.5% / −20.9% vs −3.1% placebo | Jastreboff, NEJM 2022; NCT04184622 |
| SURMOUNT-2 | Phase 3, RCT, in type 2 diabetes | 938 | 10 / 15 mg SC weekly | 72 wks | −12.8% / −14.7% vs −3.2% placebo | Garvey, Lancet 2023; NCT04657003 |
| SURMOUNT-3 | Phase 3, RCT, after 12-wk intensive lifestyle lead-in | 806 | Max tolerated (10/15 mg) | 72 wks | −18.4% additional, vs +2.5% placebo | Wadden, Nat Med 2023; NCT04657016 |
| SURMOUNT-4 | Randomised WITHDRAWAL after 36-wk open-label lead-in | 670 | Max tolerated | 88 wks | Continue: −5.5% further. Withdraw to placebo: +14.0% REGAINED | Aronne, JAMA 2024; NCT04660643 |
| SURMOUNT-5 | Phase 3b, OPEN-LABEL, active-controlled head-to-head | 751 | Max tolerated vs semaglutide | 72 wks | −20.2% vs semaglutide −13.7%, p<0.001 | Aronne, NEJM 2025; NCT05822830 |
| SURPASS-2 | Phase 3, RCT, type 2 diabetes, active-controlled | 1,879 | 5 / 10 / 15 mg vs semaglutide 1 mg | 40 wks | HbA1c −2.01 to −2.30% vs −1.86% | Frías, NEJM 2021; NCT03987919 |
| SURPASS-CVOT | Phase 3, cardiovascular outcomes, vs dulaglutide | 13,299 | Max tolerated | ~4.5 yrs | Non-inferior for MACE; not superiority vs placebo | Nicholls, 2024; NCT04255433 |
1. They are means, not promises. A −20.9% mean in SURMOUNT-1 contains people who lost far more and people who lost almost nothing. A trial average tells you what happened to a population; it does not tell you what will happen to you.
2. Every one is an FDA-APPROVED SUBCUTANEOUS INJECTION. No trial in this table tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet. When these figures appear on a page selling a compounded ODT, evidence has been moved across a dosage form without justification.
3. All were funded by Eli Lilly, which manufactures tirzepatide. That is normal in drug development and does not make the results false — these are large, peer-reviewed studies. It belongs in the citation anyway, and it matters most in SURMOUNT-5, where the funder made the winning drug and the trial was open-label.
Jastreboff AM et al., N Engl J Med 2022, n=2,539 (NCT04184622). The effect rises with dose — which is precisely why a ~1mg 'microdose' cannot be expected to produce the headline result. FDA-approved subcutaneous injection.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
Dosing, titration, and what it does to your bill
| Period | Dose | What it is for |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Tolerance-building only. This dose is not intended to produce weight loss. If your provider's price is quoted at 2.5 mg, that is not the price of treatment. |
| Weeks 5–8 | 5 mg | First therapeutic dose (−15.0% in SURMOUNT-1). |
| Weeks 9–12 | 7.5 mg | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg | A common maintenance dose (−19.5%). |
| Weeks 17–20 | 12.5 mg | Escalate only if tolerated. |
| Week 21+ | 15 mg | Maximum maintenance dose (−20.9%). |
The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.
A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.
Safety, contraindications and monitoring
Tirzepatide carries a boxed warning for thyroid C-cell tumours, based on rodent data. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This is not a precaution to weigh; it is a hard stop.
Serious but less common risks include pancreatitis, gallbladder disease (cholelithiasis and cholecystitis), acute kidney injury secondary to dehydration from vomiting or diarrhoea, diabetic retinopathy complications in people with existing retinopathy, and hypoglycaemia when combined with insulin or a sulfonylurea. Severe abdominal pain radiating to the back warrants urgent assessment for pancreatitis, not a message to a chat widget.
Before starting, a clinician should establish a baseline: weight and BMI, blood pressure, HbA1c or fasting glucose, a lipid panel, and renal and hepatic function. During treatment, tolerance should be reviewed at each escalation step rather than escalated automatically on a calendar.
Percentage of participants reporting each event. Gastrointestinal effects dominate, are usually mild-to-moderate, and are most pronounced during dose escalation. Source: SURMOUNT-1, N Engl J Med 2022.
Discontinuation: what the withdrawal trial found
Aronne LJ et al., JAMA 2024, n=670 (NCT04660643). After a 36-week open-label lead-in, participants randomised to placebo regained ~14% of body weight over the following 52 weeks; those who continued lost a further ~5%. This is the single most important trial for understanding the true cost of treatment.
In SURMOUNT-4 — the randomised withdrawal trial — participants taken off tirzepatide after a 36-week lead-in regained roughly 14% of body weight over the following year, while those who continued lost a further ~5%. This is the trial that most changes the arithmetic of treatment, and it is almost never cited on a pricing page.
The consequence is financial as much as clinical. If holding the result requires holding the medication, then the figure that matters is not the introductory price, and not even the annual price. It is the indefinite monthly price. Anyone selecting a provider on the strength of a first-month rate is optimising the wrong variable entirely.
Questions to ask your clinician
- Given my history — specifically thyroid, pancreatic and gallbladder — is a GLP-1 appropriate for me at all?
- What baseline laboratory work will you order before I start?
- What is my target dose, and how quickly will we escalate?
- Which side effects should make me call you rather than wait it out?
- What is the plan for maintenance, and what happens if I stop?
- Will I see the same clinician at each follow-up, or a different one each time?
Compounded, brand, microdose, ODT — four different products
These words are used interchangeably in marketing and they are not interchangeable at all. The distinction decides what evidence applies to what you are actually buying.
| Product | Regulatory status | Trial evidence |
|---|---|---|
| Brand Zepbound / Mounjaro (injection) | FDA-approved. Reviewed for safety, effectiveness and quality before marketing. | Direct. SURMOUNT and SURPASS tested exactly this product. |
| Brand Foundayo (oral, orforglipron) | FDA-approved. Its own trial programme. | Direct, for that product. |
| Compounded tirzepatide (injection, full dose) | NOT FDA-approved. No premarket review of safety, effectiveness or quality. | None for the compounded product itself. Same molecule, same route — but the product in your hand was never in a trial. |
| Microdose (~1 mg/wk) | NOT FDA-approved. | None. Sits BELOW every dose in SURMOUNT (5/10/15 mg). Expect a smaller effect. |
| ODT / oral compounded | NOT FDA-approved. | NONE. No trial has ever tested it. Oral bioavailability for these peptides is a real pharmacological problem and is unpublished for this product. |
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
Adverse events: the figure almost every site gets wrong
Source: FDA GLP-1 webpage, reporting 1,700+ adverse events associated with compounded semaglutide and tirzepatide as of May 21, 2026 — against the 775 total, Feb 2025 figures from February 2025 that almost every comparison site is still quoting. Reports are voluntary and do not establish causation, but the trend is the point.
As of 21 May 2026, the FDA reports having received more than 1,700 adverse events associated with compounded semaglutide and tirzepatide. That is more than double the figure still in circulation, in roughly fifteen months.
Adverse-event reports are voluntary, are not adjudicated, and do not by themselves establish causation. That caveat is real and we will not drop it. But a site that quotes the 2025 number in mid-2026 is not being cautious — it is being out of date, and in a direction that flatters the product it is paid to sell.
This matters far beyond one study, because it exposes the flaw in the whole ‘personalized dosing’ defence. Adding B12 was one of the commonest ways compounders argued their product was not “essentially a copy” of the approved drug — a clinical difference that kept them inside the law. The finding shows that the additive did not merely differentiate the product on paper. It chemically changed it, into something nobody has tested in a human being.
What to do: if you are taking a compounded tirzepatide that contains B12 — and many do, often marketed as ‘tirzepatide + B12’ or ‘with methylcobalamin’ — ask your provider and your pharmacy, in writing, whether they have tested for adduct formation. Most will not have. That answer is itself information.
In the 30 April 2026 Federal Register notice (docket 2026-08552), the agency stated that there is no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk — and went out of its way to clarify that supply and affordability are not what the statute means by clinical need.
In plain terms: there are FDA-approved products; they work; patients can be treated with them. Whether a patient can afford them is a different problem, with a different set of policy tools.
That single sentence does enormous work. Every compounded-GLP-1 marketing page in America is, at bottom, an affordability argument. The agency has now said, on the record, that affordability is not a legal basis for compounding these drugs. If you are choosing a compounded programme because it is cheaper, you should know that the regulator has explicitly said that reason does not count.